Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Abstract: The present invention provides fusion proteins containing cytokines and novel CD47 antibodies or immunologically active fragments thereof, as well as pharmaceutical compositions containing such fusion proteins that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation. These fused proteins have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination.

Abstract: This invention provides a kind of fuel filler cap actuator and automotive vehicle, comprising screw shaft, rotor, housing, first reset spring, lock block and lock block driving device; Under the action of the lock block driving device, the lock block can be rotated between the locking angle and the unlocking angle; the lock block driving device adopts an electromagnetic drive method to drive the lock block. This avoids the use of a motor drive, and achieves locking/unlocking of the fuel filler cap through the mutual interaction of the first and second magnet, which significantly reduce operational costs and increase life expectancy.

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Abstract: A translation lookaside buffer (TLB) management method and a multi-core processor are provided. The method includes: receiving, by a first core, a first address translation request; querying a TLB of the first core based on the first address translation request; determining that a first target TLB entry corresponding to the first address translation request is missing in the TLB of the first core, obtaining the first target TLB entry; determining that entry storage in the TLB of the first core is full; determining a second core from cores in an idle state in the multi-core processor; replacing a first entry in the TLB of the first core with the first target TLB entry; storing the first entry in a TLB of the second core. Accordingly, a TLB miss rate is reduced and program execution is accelerated.

Abstract: The present disclosure provides a semiconductor device. The semiconductor device includes a semiconductor substrate with a well region and a drift region in the semiconductor substrate; one or more counter-doped regions in the drift region, the plurality of counter-doped regions being directly below the second insulating structure and aligned along a direction vertical to a surface of the semiconductor substrate to divide the drift region into a plurality of parts and the plurality of counter-doped regions in the drift region being separated by the drift region. The semiconductor device further includes a gate structure on the semiconductor substrate, the gate structure covering a portion of the well region and a portion of the drift region; and a source electrode in the well region on one side of the gate structure and a drain electrode in the drift region on another side of the gate structure.

Abstract: A method for accessing an entry in a translation lookaside buffer and a processing chip are provided. In the method, the entry includes at least one combination entry, and the combination entry includes a virtual huge page number, a bit vector field, and a physical huge page number. The physical huge page number is an identifier of N consecutive physical pages corresponding to the N consecutive virtual pages. One entry is used to represent a plurality of virtual-to-physical page mappings, so that when a page table length is fixed, a quantity of entries in the TLB can be increased exponentially, thereby increasing a TLB hit probability, and reducing TLB misses. In this way, a delay in program processing can be reduced, and processing efficiency of the processing chip can be improved.

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Abstract: The invention provides a method for synthesizing a mesoporous zeolite ETS-10 containing a metal without a templating agent. The method according to the invention comprises the steps of: mixing a silicon source with a NaOH solution to obtain a mixed solution so that the content of Na2O in the mixed solution is 10.0% to 20.0% by weight; adding a KOH or KF solution so that the content of K2O is 10.0% to 25.0% by weight and stirring it well; adding a titanium source solution and stirring it well; adding a precursor compound containing metal Ni and/or Co and stirring it well; and subjecting it to a crystallization reaction to obtain the mesoporous zeolite ETS-10. The mesoporous zeolite ETS-10 obtained by the invention has a specific surface area of 320 to 420 m2/g, a mesoporous volume of 0.11 to 0.21 cm3/g, and thus can be used as a catalyst and a support thereof in synthesis industry for macromolecular fine chemicals.

Abstract: A curable organopolysiloxane composition is provided. The curable organopolysiloxane composition comprises: (A) a diorganopolysiloxane having at least two silicon-bonded alkenyl groups per molecule; (B) an organopolysiloxane resin; (C) a mixture of (C1) a diorganopolysiloxane endblocked with silicon-atom bonded hydrogen atoms at both molecular terminals and (C2) an organohydrogenpolysiloxane having at least three silicon-bonded hydrogen atoms per molecule; (D) a polyether having at least one aliphatic unsaturated group per molecule; and (E) a hydrosilylation catalyst.

Abstract: The present disclosure provides a method for forming a semiconductor device, including: providing a semiconductor substrate; forming a well region and a drift region in the semiconductor substrate; and forming one or more counter-doped regions in the drift region, the one or more counter-doped regions being aligned along a direction vertical to the semiconductor substrate to divide the drift region into a plurality of parts. The semiconductor fabrication method also includes: forming a gate structure on the semiconductor substrate, the gate structure covering a portion of the well region and a portion of the drift region; and forming a source electrode in the well region on one side of the gate structure and a drain electrode in the drift region on another side of the gate structure.

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Abstract: The present disclosure relates to synthesis of porous polymer networks and applications of such materials. The present disclosure relates to a method of fabricating of a porous polymer network comprising: (a) providing: (i) a first reactant comprising a plurality of compounds comprising at least one acetyl group, said plurality of compounds comprising at least one compound type, and (ii) a second reactant comprising an alkylsulfonic acid, and (b) creating a solution of said reactants, (c) casting said solution in a form, and (d) treating said solution under such conditions so as to produce a porous polymer network.

Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

Abstract: A Lateral Diffusion Metal Oxide Semiconductor (LDMOS) device and its manufacturing method are presented. The LDMOS device comprises a first region that has a first conductivity type; a drift region that has a second conductivity type in the first region, wherein the second conductivity type is opposite to the first conductivity type; and a plurality of second regions that have the first conductivity type in the drift region, wherein the second regions are separated from each other and extend to the first region along a depth direction of the drift region. This LDMOS device has an higher Breakdown Voltage and thus better performance than conventional LDMOS devices.

Abstract: A UV curable silicone composition, comprising: A) an alkenyl-containing organopolysiloxane that has at least two alkenyl groups in each molecule, at least one alkenyl group on each terminus; B) a photoinitiator; C) a mercapto-functional organopolysiloxane that comprises 2 or more mercapto groups per molecule; D) a pigment; and one or both of E) and F), where E) is a silica and F) is a solvent comprising a organopolysiloxane having ?12 silicon atoms.